Axial Therapeutics, Inc.

California Institute of Technology

Transient Electronics, Inc.

Other

Axial Biotherapeutics, Inc.

Anthony Stewart Campbell

John A Rogers

Sarkis K Mazmanian

Timothy R Sampson

David H Donabedian

Hitesh Bhagat

Christopher Poirier

Ryan Barrett

Winston E Henderson

Bridget McCarthy Cole

Alessandra Bartolozzi

Carmichael S Roberts

Eric S Metcalf

Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.

Sustained release solid dosage forms for modulating the colonic microbiome

The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.

Inhibitors of microbially induced amyloid

The present disclosure provides compounds useful for the prevention of amyloid formation and the treatment of amyloid related disorders, including synucleopathies such as Parkinson's Disease.

The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Systems and methods of the invention generally relate to altering the functionality of a non-transient electronic device. A container holding an agent is located proximal to a non-transient electronic device capable of performing at least one function. The agent is capable of rendering the device incapable of performing the at least one function. The container is configured to controllably release the agent to the electronic device in a variety of passive and active eventualities.

Controlled transformation of non-transient electronics

A suspension gauge with an inner rod (12) sliding in an outer tube (10). The marker ring (18) slides along the calibrated scale of the inner rod marking the deflection of the suspension system at various loaded and unloaded positions. In addition a locking mechanism (16)(24)(26)(28)(30)(32)(34)(36)(38) is provided at the lower end of the gauge as an attachment device to the rear axle hub. At the upper end of the gauge a swivel block (22) and spring clip (14) are provided to attach the gauge to the motorcycle rear fender.

Growing community of inventors

Framingham, MA, United States of America

Anthony Stewart Campbell